Clinical Trial Update: Adjuvant Pazopanib in Stage I NSCLC [Phase 2, Phase 3]

View source ↗

Summary

Clinical trial update on adjuvant pazopanib in stage I non-small cell lung cancer (Phase 2/Phase 3) finished recruitment; status completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• Pazopanib (Pazopanib)

Snippet

Sponsor: Intergroupe Francophone de Cancerologie Thoracique | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2, Phase 3 | Status: COMPLETED